Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154

We thank Galligan et al. (1) for their interest in our observation (2) on the successful treatment of immune checkpoint inhibitor–induced diabetes with infliximab. First, we agree with the commenters that intra-articular steroid injection could have contributed slightly to the development of insulin resistance. However, an intra-articular injection is not expected to have as much impact on insulin sensitivity as systemic corticosteroid...